Lundbeck ready with plan for important launch: FDA will decide Wednesday
Wednesday evening in local time, Lundbeck and its partner Otsuka eagerly awaits the US Food and Drug Administration’s (FDA) formal decision on whether schizophrenia drug Rexulti can be used as a treatment for elderly patients with Alzheimer’s who suffer from agitation.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.